Brief: Recro And Biocorrx Expand Development And Manufacturing Relationship To Support Bicx104, An Implantable Naltrexone Pellet For The Treatment Of Opioid Use Disorder
08/09/2021 12:33
Sept 8 (Reuters) - Recro Pharma Inc REPH.O :
* RECRO AND BIOCORRX EXPAND DEVELOPMENT AND MANUFACTURING
RELATIONSHIP TO SUPPORT BICX104, AN IMPLANTABLE NALTREXONE
PELLET FOR THE TREATMENT OF OPIOID USE DISORDER
* RECRO PHARMA - WILL PROVIDE ANALYTICAL VALIDATION SERVICES
AND
CGMP MANUFACTURING OF REGISTRATIONAL BATCHES OF BICX104
Source text for Eikon: ID:nGNX4kjtB6
Further company coverage: REPH.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Biocorrx
See all newsBrief: BioCorRx Submits Fast Track Application To FDA For Bicx104, An Implantable Biodegradable Naltrexone Pellet For The Treatment Of Opioid Use Disorder
Brief: Biocorrx Announces Completion Of Treatment Phase Of Study Subjects And Preliminary Safety Data From Phase I Clinical Trial Of Bicx104
Brief: BioCorRx Partners With Government Plus To Expand Its Beat Addiction Recovery Program In The United States
Brief: Biocorrx Completes Final Subject Enrollment In Phase I Clinical Trial Of Bicx104, An Implantable Naltrexone Pellet For The Treatment Of Opioid Use Disorder
Brief: BioCorRx Begins Recruitment for Clinical Trial of BICX104